Faculty profile

Adam Shlien

ResearcherUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.

Adam Shlien

Researcher

Health Sciences

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
44 publications in the last five years, latest in 2026.
Senior (last) author on 5 recent papers, a sign of leading a research group.
Principal investigator on 4 research grants (4 CIHR), most recently in 2024.
Supervised 3 trainees who won CIHR awards, most recently in 2026.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

467

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Cancer Early Diagnosis Machine Learning Molecular Evolution Rna Sequencing Sarcoma Transcriptomics Genomics

Latest papers

Prior therapy defines mutation profiles in childhood cancer at relapse.
Nature · 2026 · senior author
High clinical utility of comprehensive multi-omic molecular profiling of rare and hard-to-diagnose pediatric tumors.
Research square · 2026
High clinical utility of comprehensive multi-omic molecular profiling of rare and hard-to-diagnose pediatric tumors.
medRxiv : the preprint server for health sciences · 2026

All 91 publications

Latest funding

Rapid precision diagnostics for leukaemia: developing RNA-based classifiers for care across Canada and globally
CIHR · 2026 · Supervisor
$140,000
Targetable Gene Dependencies in Ewing Sarcoma Subtypes
CIHR · 2025 · Supervisor
$120,000
Addressing molecular heterogeneity of leiomyosarcoma: Implementing molecular subgroups, defining its early origins to direct the selection of novel drug combinations
CIHR · 2025 · Co-investigator
$1,204,876

All 15 grants and awards

91 publications.

Prior therapy defines mutation profiles in childhood cancer at relapse.

Layeghifard M, Díaz-Gay M, Bergstrom EN, Mahendralingam MJ, Light N, Blay S, Nash JO, Anderson ND, Au JN, Davidson S, Ballester PL, Wen T, Daud SK, Edward LM, Ashiqul Islam SM, Khandekar A, Otlu B, Brunga L, Hammad R, Nassif S, Thacker NH, Feltham T, Fuentes-Bolanos NA, Wong-Erasmus M, Levine MF, Miller KE, Shukla NN, Kinnaman MD, Glodzik D, Portwine C, Millson S, Zorzi AP, Mikhail M, Fernandez CV, Wheaton L, Gundem G, Kung AL, Tabori U, Mayoh C, Papaemmanuil E, Cowley MJ, Malkin D, Villani A, Alexandrov LB, Shlien A

Nature2026Senior author

DOI: 10.1038/s41586-026-10803-1 PMID: 42486975

High clinical utility of comprehensive multi-omic molecular profiling of rare and hard-to-diagnose pediatric tumors.

Sullivan AJ, Khuong-Quang DA, Villani A, Wong-Erasmus M, Trinder S, Lau LMS, Barahona P, Altekoester AK, Rumford M, Dias K, Mayoh C, Fuentes-Bolanos NA, Courtney EK, El-Kamand S, Cui L, Lin A, Davidson S, Yuki KE, Sanders N, Staunton J, Jessop S, Sriharan S, Alvaro F, Anazodo A, Bhatia K, Campbell M, Foresto S, Gottardo NG, Kirby M, Khaw SL, Manoharan N, McCowage G, Moore AS, Nicholls W, O'Connor M, Padhye B, Ryan AL, Super L, Wood PJ, Davies J, D'Arcy C, Gifford AJ, Rodriguez M, Tucker KM, Pinese M, Ekert PG, Haber M, Tyrrell V, Trahair TN, Marshall GM, Shlien A, Cowley MJ, Ziegler DS

Research square2026

DOI: 10.21203/rs.3.rs-10108527/v1 PMID: 42620518

High clinical utility of comprehensive multi-omic molecular profiling of rare and hard-to-diagnose pediatric tumors.

medRxiv : the preprint server for health sciences2026

DOI: 10.64898/2026.07.25.26358936 PMID: 42619885

Extensive and differential platinum chemotherapy mutagenesis in livers of children.

Wenger A, Vannier JB, Lee-Six H, Loesch R, Emanuelli G, Dave M, Layeghifard M, Lawson ARJ, Abascal F, Nicola PA, Treger TD, Ogbonnah T, Parks C, Oliver TRW, Kennedy J, Hodder A, Anderson ND, Torres Silva FL, Trinh MK, Dowe T, Habarwaa M, Sun JJ, Assia-Zamora S, Cortes-Cerisuelo M, Jassem W, Town C, Dhawan A, Jain V, Straathof K, Deheragoda M, Martincorena I, Palm L, Hutchinson JC, Coorens THH, Trayers C, Yuneva M, Heaton N, Shlien A, Zen Y, Rouhani FJ, Behjati S

Science (New York, N.Y.)2026

DOI: 10.1126/science.ady0339 PMID: 42721248

An international framework for clinical translation of molecular classifiers in osteosarcoma.

Marinoff AE, Nathrath M, Shulman DS, Whittle SB, Pavisic J, Spentzos D, Albert CM, Nash JO, Shlien A, Cortés-Ciriano I, Marchais A, López-Fuentes E, Curtis C, Sweet-Cordero EA, Gorlick R, DelRocco N, Chugh R, Tap WD, Flanagan AM, Gaspar N, Crompton BD, Reed DR, Janeway KA, Grohar PJ, Livingston JA, Roberts RD

NPJ precision oncology2026

DOI: 10.1038/s41698-026-01456-4 PMID: 42086782

ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis.

Molotkova A, Deniz E, Swift M, Glasgow E, Ma J, Petro JA, Frye I, Ozdemirli M, Pesic D, Ahern GP, Suter RK, Tiwari PB, Shlien A, Toretsky J, Üren A

Cancer research communications2026

DOI: 10.1158/2767-9764.crc-26-0068 PMID: 41650465

Advancing Preclinical Biology for Ewing Sarcoma: An International Effort.

Dela Cruz FS, Stewart EA, Surdez D, Daley JD, Soragni A, Tomazou EM, Alvarez-Perez J, Feinberg TY, Amatruda JF, Ganapathi SS, Ohm JE, Heske CM, Cohen-Gogo S, Pesic D, Nash JO, Shlien A, Roundhill EA, Burchill SA, Crompton BD, Lawlor ER, Loeb DM, Delattre O, Mora J, Scotlandi K, Reed DR, Grohar PJ, Grünewald TGP, Kovar H, Bailey KM

Molecular cancer therapeutics2026

DOI: 10.1158/1535-7163.mct-25-0428 PMID: 40911901

Patterns of hypermutation shape tumorigenesis and immunotherapy response in mismatch-repair-deficient glioma.

Fernandez NR, Chang Y, Nunes NM, Dimayacyac JR, Levine A, Ringel A, Negm L, Ercan AB, Hess JM, Ahmad O, Lee C, Stengs L, Bianchi V, Edwards M, Doherty S, Chung J, Nobre L, Bennett J, Dodgshun AJ, Jones DTW, Pfister SM, Villani A, Malkin D, Ramaswamy V, Huang A, Bouffet E, Aronson M, Dirks PB, Shlien A, Getz G, Maruvka YE, Ertl-Wagner B, Hawkins C, Das A, Tabori U

Nature genetics2026

DOI: 10.1038/s41588-025-02420-x PMID: 41430480

Clinical utility of targeted RNA sequencing in cancer molecular diagnostics.

Siddaway R, Glembocki AI, Arnoldo A, Staunton J, Liu APY, Yuki KE, Yu M, Cohen-Gogo S, Shlien A, Villani A, Whitlock JA, Hitzler J, Tabori U, Levine AB, Lafrenière A, Nagy A, Chen H, Ngan BY, Somers GR, Abdelhaleem M, Chami R, Hawkins C

Nature medicine2025

DOI: 10.1038/s41591-025-03848-8 PMID: 40676318

Optimal Factors That Influence the Establishment of Successful Primary Human Soft-Tissue Sarcoma Cell Lines.

Coward VS, Dorsey J, Babichev Y, Gokgoz N, Seto A, Griffin AM, Nash JO, Brar SS, Ferguson PC, Swallow CJ, Demicco EG, Dickson BC, Shlien A, Tsoi KM, Wunder JS, Andrulis IL, Gladdy RA

Clinical cancer research : an official journal of the American Association for Cancer Research2025

DOI: 10.1158/1078-0432.ccr-25-0111 PMID: 40627444

Something wrong or missing on this profile? Suggest a correction

Adam Shlien

Research

Latest papers

Latest funding

Prior therapy defines mutation profiles in childhood cancer at relapse.

High clinical utility of comprehensive multi-omic molecular profiling of rare and hard-to-diagnose pediatric tumors.

High clinical utility of comprehensive multi-omic molecular profiling of rare and hard-to-diagnose pediatric tumors.

Extensive and differential platinum chemotherapy mutagenesis in livers of children.

An international framework for clinical translation of molecular classifiers in osteosarcoma.

ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis.

Advancing Preclinical Biology for Ewing Sarcoma: An International Effort.

Patterns of hypermutation shape tumorigenesis and immunotherapy response in mismatch-repair-deficient glioma.

Clinical utility of targeted RNA sequencing in cancer molecular diagnostics.

Optimal Factors That Influence the Establishment of Successful Primary Human Soft-Tissue Sarcoma Cell Lines.

Frequent collaborators

David Malkin

Uri Tabori

Eric Bouffet

Cynthia Hawkins

Vijay Ramaswamy

Annie Huang

Nada Jabado

Mohamed Abdelhaleem

Birgit Ertl-Wagner

Birgit Ertl-Wagner

Rosanna Weksberg

Michael Brudno

Valérie Larouche

Johann Hitzler

Gregory Costain

Sebastien Perreault

Steven Gallinger

Sevan Hopyan

Adam Fleming

Anna Goldenberg

Catherine Goudie

Nada Jabado

Victoria Forster

Ma'n Zawati

David Allan

Tania Dumont

Arun Seth

Ali Bashashati

Gino Somers

James Whitlock

Daniel Sinnett

Ute Bartels

Sonia Cellot

Sarah Levitt

Michael Sullivan

Michael Ohh

Sohrab Shah

Jordan Lerner-Ellis

Katherine Siminovitch

Jennifer Chan